Figures & data
Table I. Advantages and limitations of the clinical diagnosis of the metabolic syndrome.
Figure 1. Schematic representation of the assessment of global cardiometabolic risk using traditional risk factors and emerging cardiovascular disease risk markers.
![Figure 1. Schematic representation of the assessment of global cardiometabolic risk using traditional risk factors and emerging cardiovascular disease risk markers.](/cms/asset/306d3c1d-e8ce-4fb7-9352-50508ff965d0/iann_a_300661_f0001_b.gif)
Figure 2. Plasma: C-reactive protein (CRP) levels (top) and visceral adipose tissue accumulation measured by computed tomography (bottom) in men with the hypertriglyceridemic waist phenotype (waist ≥90 cm and triglycerides ≥2.0 mmol/L) and in men with both a low waist circumference and low plasma triglyceride levels.
![Figure 2. Plasma: C-reactive protein (CRP) levels (top) and visceral adipose tissue accumulation measured by computed tomography (bottom) in men with the hypertriglyceridemic waist phenotype (waist ≥90 cm and triglycerides ≥2.0 mmol/L) and in men with both a low waist circumference and low plasma triglyceride levels.](/cms/asset/741a6b71-e0bd-4efa-9fc5-34d487a02685/iann_a_300661_f0002_b.gif)